查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136901

全球慢性肾病药物市场2022-2029

Global Chronic Kidney Disease Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

主要驱动因素是慢性肾病患病率的增加、对治疗患者的药物的持续需求、易于获得的药物、研究和开发的增加、技术进步以及市场上老年人口的增长。预计这将成为引擎的增长。

预计对慢性肾病药物的需求不断增长将推动市场增长。

全球慢性肾脏病药物市场主要受慢性肾脏病相关药物需求增长的推动。根据美国疾病控制与预防中心 2021 年报告，慢性肾病不断上升会导致更多人死亡。这是一场未被充分认识的公共卫生危机。它影响了美国大约 3700 万人，占成年人口的 15%，即超过七分之一的成年人。肥胖、高血压和糖尿病是慢性肾病的常见原因。因此，对慢性肾病的治疗剂的需求不断增加。

主要市场进入者不断提高的技术进步正在推动市场的增长。市场上正在进行许多新的研究和创新。例如，2021年4月，阿斯利康宣布Farxiga（达格列净）获得美国食品药品监督管理局的批准。 Faxiga 是一种钠-葡萄糖协同转运蛋白 2 的抑製剂，用于最大限度地降低与估计的肾小球滤过率、心血管死亡、终末期肾病和慢性肾病相关的风险。

慢性肾病药物的高成本和副作用阻碍了市场增长。

由于开具各种药物以尽量减少慢性肾脏病的发展，从而导致慢性肾脏病患者出现肾功能不全等并发症，因此存在药物相关并发症、成本高、监管审批程序严格、模棱两可等风险。症状延迟慢性肾病的诊断、仿製药选择趋势和药物专利到期。

本报告介绍了全球慢性肾病药物市场，有 40 多个市场数据表、45 多个图表和 200 页（估计）。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 对慢性肾病药物的需求增加
      • 技术进步的增加
    • 约束因素
      • 慢性肾病药物成本高
      • 与 CKD 药物相关的风险
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力
  • 未满足的需求
  • 流行病学
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类别

  • 钙拮抗剂
  • ACE抑製剂
  • B 受体阻滞剂
  • 利尿剂
  • 红细胞生成刺激剂 (ESAS)
  • 其他

第 8 章给药途径

  • 口语
  • 皮下给药
  • 静脉给药

第 9 章按分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • 辉瑞公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca Plc.
  • Kissei Pharmaceutical Co
  • AbbVie Inc.
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Akebia Therapeutics

第13章 全球慢性肾病药物市场-DataM

简介目录
Product Code: DMMD790

Market Overview

The Chronic Kidney Disease Drugs Market was valued at US$ 10,923.29 million in 2021 and is estimated to reach US$ 19,427.41 million by 2029, growing at a CAGR of 6.58% during the forecast period (2022-2029).

Chronic kidney disease, also known as chronic kidney failure, describes the gradual loss of kidney function. Kidneys filter the wastes and excess fluids from blood, which are then excreted in the urine.

Market Dynamics

The major driving forces are the increasing prevalence of chronic kidney disease, the continuous requirement for drugs to treat the patients along with easy availability, the increase in research and development, technological advancements and the rising geriatric population are expected to drive market growth.

The rising requirement for chronic kidney disease drugs is expected to drive market growth.

The global market for chronic kidney disease drugs is primarily driven by the rising demand for drugs related to chronic kidney disease. According to the Centre for Disease Control and Prevention report 2021, the increase in chronic kidney disease causes more deaths. It is an under-recognized public health crisis. It affects approximately 37 million people in the U.S., equivalent to 15% of the adult population or more than one in seven adults. The high prevalence of obesity, hypertension and diabetes are some of the reasons that are causing chronic kidney disease. Hence, increasing demand for drugs for the treatment of chronic kidney disease.

Increasing technological advancements by the major key players are driving the market's growth. Various novel research studies and innovations are taking place in the market. For instance, in Apr 2021, AstraZeneca announced the approval of Farxiga (dapagliflozin) by the U.S. Food and Drug Administration. Farxiga is an inhibitor of sodium-glucose cotransporter 2 used to minimize the risk associated with estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease, and chronic kidney disease patients.

Chronic kidney disease drugs' high cost and side effects will hamper the market's growth.

The risks associated with chronic kidney disease drugs such as medication-related complications as a variety of medications are prescribed to minimize the chronic kidney disease growth that leads to some complications such as renal functions degradation of the patient, the high cost, the stringent regulatory approval process, delayed diagnosis of chronic kidney disease due to vague symptoms, the inclination to generic medication options, and the patent expiry of drugs.

Segment Analysis

The calcium channel blockers segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The calcium channel blockers segment is the highest market holder in the global chronic kidney disease drugs market. The increased number of chronic kidney diseases leads to the growing demand for treatment drugs and research activities. Calcium channel blockers prevent, treat or improve symptoms in various conditions, such as high blood pressure and coronary artery disease, which can increase the risk of chronic kidney diseases. Presently, dominant calcium channel blockers utilized across the world are phenyl alkyl amines (verapamil), benzothiazepines (diltiazem), and dihydropyridines (nifedipine and amlodipine). A report published in Aug 2022 titled "Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers" reported that around 65-95% of patients with chronic kidney disease are suffering from hypertension. The first line of treatment drugs for hypertension are Calcium channel blockers. These calcium channel blockers act as antihypertensive medicines used widely due to their high tolerability, efficacy in lowering the level of blood pressure, and hypertension-related cardiovascular or renal consequences. For instance, in Aug 2022, AstraZeneca from DELIVER phase III trial released detailed results showing Farxiga reducing cardiovascular death or heart failure.

Geographical Analysis

North America holds the largest market share of the global chronic kidney disease drugs market.

North America dominates the global chronic kidney disease drug market, primarily attributed to the growing prevalence of chronic kidney diseases, kidney failure, and diabetes. The rapid adoption of drugs for CKD is likely to enhance the growth of chronic kidney disease drugs. Furthermore, factors such as the high spending of GDP on healthcare, growing government initiatives, and reimbursement policies in advanced medical treatment options are likely to enhance the growth of the region's chronic kidney disease drugs market.

Moreover, extensive research activities are undertaken by the most prominent players in the area, and the rising demand for technologically advanced treatment will propel the market. Also, key players manufacturing chronic kidney disease treatment drugs are boosting the market. For instance, in Jul 2021, Bayer announced the approval of Kerendia (Finerenone), first non-steroidal, mineralocorticoid receptor antagonist, by the U.S. FDA. Finerenone is used to minimize the risk of decline in estimated glomerular filtration rate, cardiovascular death, end-stage kidney disease and chronic kidney disease patients with type 2 diabetes.

Competitive Landscape

The chronic kidney disease drug market is moderately competitive with local and global companies. Key players contributing to the market's growth are Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc., Kissei Pharmaceutical Co, AbbVie Inc., GlaxoSmithKline Plc, Amgen Inc., Akebia Therapeutics and more.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the cardiac ablation devices market. For instance, in Aug 2022, CSL Limited announced the completion of the acquisition of Vifor Pharma AG. CSL got all the necessary regulatory clearances required for Vifor's acquisition.

Pfizer Inc.:

Overview:

Pfizer Inc. is a multinational pharmaceutical company that also works in the biotechnology domain. It was established in 1849 and is headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, and immunology.

Product Portfolio:

RETACRIT: Retacrit is a kind of erythropoietin man-made protein made in a laboratory. It is an erythropoiesis-stimulating agent used to treat the anemia caused due to chronic kidney disease.

The global chronic kidney disease drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising requirement for chronic kidney disease drugs
      • 4.1.1.2. Increasing technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of chronic kidney disease drugs
      • 4.1.2.2. Risk associated with CKD drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Epidemiology
  • 5.4. Supply chain Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Calcium Channel Blockers*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. ACE Inhibitors
  • 7.4. B- Blockers
  • 7.5. Diuretics
  • 7.6. Erythropoiesis-Stimulating Agents (ESAS)
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subcutaneous
  • 8.4. Intravenous

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi S.A.
  • 12.3. F. Hoffmann-La Roche Ltd.
  • 12.4. Teva Pharmaceutical Industries Ltd.
  • 12.5. AstraZeneca Plc.
  • 12.6. Kissei Pharmaceutical Co
  • 12.7. AbbVie Inc.
  • 12.8. GlaxoSmithKline Plc
  • 12.9. Amgen Inc.
  • 12.10. Akebia Therapeutics

LIST NOT EXHAUSTIVE

13. Global Chronic Kidney Disease Drugs Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us